Cytosorbents (CTSO) Receivables - Net (2011 - 2026)

Cytosorbents' Receivables - Net history runs 16 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• Quarterly Receivables - Net fell 6.76% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 6.76% YoY) and the FY2025 annual result came in at $7.6 million, up 3.14% from the prior year.
• Receivables - Net was $7.2 million for Q1 2026 at Cytosorbents, down from $7.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $7.8 million in Q2 2024 and bottomed at $4.6 million in Q1 2022.
• A 5-year average of $6.5 million and a median of $6.8 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net fell 10.14% — and 2023, when it soared 35.85%.
• Cytosorbents' Receivables - Net stood at $5.7 million in 2022, then gained by 6.92% to $6.1 million in 2023, then advanced by 20.85% to $7.3 million in 2024, then rose by 3.14% to $7.6 million in 2025, then slipped by 5.27% to $7.2 million in 2026.
• Business Quant data shows CTSO's Receivables - Net at $7.2 million in Q1 2026, $7.6 million in Q4 2025, and $7.4 million in Q3 2025.